Truvian’s Post

As we approach Rare Diseases Day, TMC are running a webinar on how the Medical Services approach needs to be different for orphan and rare diseases. The Webinar is on Thursday and the link to register is in the attached post. #tmcpharma

Have you ever thought how de-identified lab data can accelerate the development of your new therapy? #DataLicensing #QuestHealthcareAnalyticsSolutions #LabData #DeidentifiedData

How can we ensure essential treatments reach those in need in a world of growing payer restrictions? https://ow.ly/nS5q50SV0mW The Dedham Group, in collaboration with MMIT (Managed Markets Insight & Technology), surveyed 300+ pharma and biotech leaders to explore current and future patient access challenges. Discover the insights shaping the future of patient access with The State of Patient Access – Inaugural Report by clicking the link in this post.

2024 has marked a new phase for biopharma partnerships and doing the “exact” deal is more important than ever to advance innovation and accelerate groundbreaking new therapies to patients. I look forward to joining a panel discussion at #LSXUSA, September 11 in Boston, MA. I’ll be discussing how strategic fit and creative deal-making are shaping the partnerships that will deliver positive, sustainable and meaningful value to patients. Come join us if you’re attending: https://bit.ly/46JeXh3 #ScienceFirstForPatients #ChangingTomorrow

Developing new medicines is a long, resource-intensive process, full of uncertainties. Our research into digital twinning allows us to simulate drug trials on virtual patients, accelerating early assessments of safety and efficacy with greater precision, and potentially reducing the need for large-scale clinical trials. This innovative approach is transforming our R&D landscape. #DigitalTwinning

Thrilled to attend #DIAEurope2024, where industry leaders converged to explore cutting-edge advancements in healthcare. From insightful discussions to impactful networking, the conference provided an invaluable platform to delve into the future of pharmaceuticals and regulatory affairs. Grateful for the enriching experiences and connections made! #HealthcareInnovation #Regulatory #clinicalresearch #clinicaltrial #gcp #pharmacovigilance #drugdiscovery #drugdevelopment #drugsafety

With marked shifts in the pursuit and grant of high-order designations, important questions arise: -What factors are behind the sharp downturns in CDER breakthrough designations? -What about the sharp post-pandemic upturn in high-order designations by CBER? -Could this represent a shifting enthusiasm towards advanced therapies? Our latest report, based on recent data from the FDA, offers critical insights into these market shifts. Discover what these changes mean for drug developers and gain a deeper understanding of the evolving landscape of high-order designations. Read the full report here: https://lnkd.in/d8fYYTPW #HighOrderDesignations #FDAInsights #DrugDevelopment #AdvancedTherapies

"Discover the latest strategies in drug delivery! Join our seminar on innovative strategies for drug delivery. Learn from industry experts and stay updated on the most recent advances in this critical field. Don't miss this opportunity to expand your knowledge in drug delivery! #DrugDelivery #PharmaceuticalInnovation"

Day 2 Highlight at World Orphan Drug Congress in Boston 🌐 Industry insights on partnering in the rare disease space struck a chord with us. Panelists discussed the advantages of partnerships between large and small biopharma and pharma companies. While established organizations can bring more resources to the development of medical treatments, smaller companies often have a deeper understanding of rare diseases and innovative approaches to problem-solving. 💡 Our agile team at Alethium Health has designed our clinical trial platform to anticipate nuanced needs and challenges before they happen. We’ve optimized trials by adjusting for patient or caregiver struggles, such as incorporating televisits and providing additional translations, to make clinical trials globally accessible at exceptional speed, reduced costs, and minimal risk. 🚀 #ClinicalTrials #OrphanDrugCongressUSA #DigitalClinicalTrials #RareDisease

Techniques and platforms used for immunoassays vary greatly based on the target, treatment type, and desired endpoints. Read our blog to figure out which one is best for your clinical trial needs. https://hubs.ly/Q02F0jVX0 #translationalresearch #immunoassays #drugdevelopment #biomarkers